Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Open in API
Filings indexed 208 across all filing types
Latest filing 2025-01-27 Regulatory Filings
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing that the company received final EMA clearance to initiate its Phase 2 clinical trial. It is not an earnings release, financial report, or presentation, nor does it involve dividends, share issues, M&A, or management changes. It is a general regulatory announcement regarding clinical trial approval, which does not fit any specialized category, making “Regulatory Filings (RNS)” the appropriate fallback.
2025-01-27 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a news release/press announcement by Thiogenesis Therapeutics describing a corporate presentation at a United Mitochondrial Disease Foundation webcast. It contains no financial results, capital‐raising details, share transactions, or formal regulatory filings. It is not an Annual or Interim Report, earnings release, or management discussion, nor is it a formal investor deck. It therefore does not fit any specialized category and is classified under the fallback Regulatory Filings (RNS).
2024-12-10 English
News release - English.pdf
Share Issue/Capital Change Classification · 82% confidence The document is a corporate press release announcing multiple corporate developments, most notably the issuance of 521,800 new shares upon exercise of Finder’s Options (a capital change event). Under our taxonomy, announcements of new share issues or other capital changes map to Share Issue/Capital Change (SHA). It is not an earnings release, proxy statement, or full financial report, nor is it merely a report publication notice. Therefore, the correct classification is SHA.
2024-11-28 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for the three and nine months ended September 30, 2024 and 2023. It contains detailed financial statements including statements of financial position, operations, changes in shareholders' equity, and cash flows. It also includes notes on accounting policies and estimates. The document explicitly states it is prepared in accordance with IAS 34 'Interim Financial Reporting' and IFRS standards. The presence of interim financial statements for a period shorter than a full fiscal year, with substantive financial data and analysis, clearly identifies this as an Interim / Quarterly Report. The document is not a full annual report, nor is it an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement. 9M 2024
2024-11-19 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the three and nine months ended September 30, 2024. It contains detailed discussion of the company's business, clinical trials, regulatory status, and financial reporting framework. It references unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2024, prepared under IAS 34 Interim Financial Reporting. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The MD&A is a management report explaining financial results, business trends, and outlook, which fits the definition of Management Reports (MDA). It is not an earnings release (ER) because it contains detailed discussion and analysis, not just key highlights. It is not an Annual Report (10-K) because it covers an interim period (three and nine months). It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive financial and operational analysis. Therefore, the correct classification is Management Reports (MDA).
2024-11-19 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings by the CEO of Thiogenesis Therapeutics, Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2024. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references an interim report but does not include the report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is 3053 characters, which is relatively short and consistent with a certification letter rather than a full report.
2024-11-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.